XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 12 - Segment Information - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Total revenues $ 54,696 $ 34,172 $ 125,456 $ 95,973
Gross profit (loss) 28,627 20,653 73,978 62,278
Operating expenses 31,139 20,631 69,166 54,216
Operating (loss) income (2,512) 22 4,812 8,062
Nonoperating (income) expense, net (171) 5,749 1,192 10,651
(Loss) earnings before income taxes (2,341) (5,727) 3,620 (2,589)
Operating Segments [Member]        
Total revenues [1] 54,696 34,172 125,456 95,973
Gross profit (loss) 28,727 20,793 74,174 62,354
Operating Segments [Member] | Sterilization and Disinfection Control [Member]        
Total revenues [1] 13,831 13,077 43,014 37,696
Gross profit (loss) 9,945 9,308 31,859 28,098
Operating Segments [Member] | Biopharmaceutical Development [Member]        
Total revenues [1] 12,756 8,711 32,188 23,791
Gross profit (loss) 8,768 4,616 20,061 15,294
Operating Segments [Member] | Calibration Solutions [Member]        
Total revenues 11,624 12,384 33,769 34,486
Gross profit (loss) 6,090 6,869 18,330 18,962
Operating Segments [Member] | Clinical Genomics [Member]        
Total revenues [2] 16,485 0 16,485 0
Gross profit (loss) 3,924 0 3,924 0
Corporate, Non-Segment [Member]        
Gross profit (loss) [3] $ (100) $ (140) $ (196) $ (76)
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.
[3] Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.